News of Note: Donanemab Gains FDA Approval for Early Alzheimer’s Treatment
Stephanie Collier, MD and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Stephanie Collier, MD and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Shireen Wissa, PharmD Candidate 2025. Keck Graduate Institute School of Pharmacy, Claremont, CA.
Talia Puzantian, PharmD, BCPP. Keck Graduate Institute School of Pharmacy, Claremont, CA.
Ms. Wissa and Dr. Puzantian have no financial relationships with companies related to this material.
Heather Robles, PharmD candidate, and Talia Puzantian, PharmD, BCPP. Ms. Robles and Dr. Puzantian have no financial relationships with companies related to this material.
Stephanie Collier, MD, MPH, and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Talia Puzantian, PharmD, BCPP.
Deputy editor for The Carlat Addiction Treatment Report. Professor, Keck Graduate Institute School of Pharmacy. Claremont, CA.
Dr. Puzantian has no financial relationships with companies related to this material.
Dr. Puzantian and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to the information provided in this book.
Dr. Puzantian and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to the information provided in this book.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.